ascopubs.org

Main reasons of choice of formulation and route of triptorelin treatment initiated in patients with prostate cancer (PCa): TALISMAN study.

Adherence to standard of care (SOC) therapy for the treatment of metastatic hormone-sensitive prostate cancer (mHSPC): A single-institution analysis.
elEconomista

Ipsen announces positive top line results from phase III clinical study of Decapeptyl® (triptorelin pamoate)11.25 mg administered subcutaneously in patients with prostate cancer

Claude Bertrand, Executive Vice-President, Research & Development and Chief Scientific Officer of Ipsen stated: “The efficacy and safety of triptorelin pamoate 11.25 mg in the treatment of patients ...
The Guardian

PBS should fund drug to treat breast cancer, endometriosis and gender dysphoria, experts recommend

Triptorelin, already listed for prostate cancer, should have unrestricted use, the Pharmaceutical Benefits Advisory Committee says Follow our Australia news live blog for latest updates Get our ...
Renal & Urology News

NDA Accepted for Six-Month Prostate Cancer Treatment

The New Drug Application (NDA) by Watson Pharmaceuticals, Inc., for a six-month formulation of Trelstar (triptorelin pamoate) has been accepted for filing. Triptorelin is a luteinizing ...